viewValiRx PLC

ValiRx chief says company is at an exciting phase as it updates on two key cancer candidates

Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders"

researcher filling a sample tray
The company has made significant clinical progress with both its drug candidates

ValiRx Plc (LON:VAL) said “commercial activity” around its lead cancer drug candidate has continued as it updated on both VAL401 and next in the queue, VAL201.

Chief executive, Dr Satu Vainikka, said she looked forward to the “successful crystallisation of substantial value for patients and shareholders".

“Since the pharmaceutical industry is increasingly looking for novel new therapies in the oncology arena, I believe we are in a new and very exciting phase,” she explained.

“VAL401 has demonstrated therapeutic efficacy, VAL201 is increasingly showing its therapeutic potential and our pre-clinical compounds and platform continue to progress along the value-chain and towards the clinic.”

Lung cancer treatment 

Preparations are currently being made to take the former which is being developed to tackle lung cancer, into final-stage clinical trials.

ValiRx said the principal investigators have now approved and signed the clinical study report and that the process of submission to and approval by the local ethics committees has commenced. 

“Detailed discussions are in progress in respect to a pivotal phase III trial,” the company said in its update. 

“Partners external to ValiRx and ValiSeek will have substantial input into the trial design, with first dosing anticipated next year.”

VAL201, meanwhile, has demonstrated “consistently high” safety and tolerability in hormone-sensitive and hormone-resistant prostate cancer patients taking part in the firm’s phase I/II trial.

Early inspection of data

Researchers have also made an inspection of the data derived from the original dosing regimen.

Highlighted was a dose-related impact on patients' physiology and chemistry.

Affected was androgen PSA (which regulates the expression of prostate cancer cells) as well as various cell and protein turnover factors important in the treatment of cancer. 

“These are in line with anticipated outcomes as far as cancer reduction is concerned,” the company added.

Quick facts: ValiRx PLC

Price: 27.1 GBX

Market: AIM
Market Cap: £16.26 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...


Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read